Entry Point Capital, LLC Adma Biologics, Inc. Call Options Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ADMA
# of Institutions
325Shares Held
190MCall Options Held
917KPut Options Held
91.6K-
Black Rock Inc. New York, NY18.6MShares$292 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$285 Million0.01% of portfolio
-
State Street Corp Boston, MA13MShares$204 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA12.6MShares$198 Million0.05% of portfolio
-
Morgan Stanley New York, NY8.6MShares$135 Million0.01% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $3.07B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...